the past threads explain all, but in a nutshell ... relenza is one of only two drugs available that are known to mitigate against the avian flu virus ... the other being tamiflu .... nations are now stockpiling these as insurance against a pandemic ... of course gsk had all but thrown out relenza as a viable drug and now that its much sought after that should also have a material effect on biotas multimillion dolar case against gsk. mediation of that dispute is due in november ... the bird flu crisis must be making gsk squirm. i wouldnt be surprised to see them offering dollars sooner rather than later.
BTA Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held